共 143 条
- [1] Amori RE(2007)Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 194-206
- [2] Lau J(2012)Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 e1369-2637
- [3] Pittas AG(2006)Sitagliptin Study 021 Group: effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2632-483
- [4] Karagiannis T(2012)2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 380 475-2317
- [5] Paschos P(2008)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 31 2315-1146
- [6] Paletas K(2014)Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study BMJ 348 g2780-128
- [7] Matthews DR(2014)Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies BMJ 348 g2366-181
- [8] Tsapas A(1999)Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 100 1134-1326
- [9] Aschner P(2013)Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery Acta Diabetol 50 123-1335
- [10] Kipnes MS(2011)The diabetic cardiomyopathy Acta Diabetol 48 173-2643